ES250249A1 - 9, 11-dihalogeno steroids - Google Patents

9, 11-dihalogeno steroids

Info

Publication number
ES250249A1
ES250249A1 ES0250249A ES250249A ES250249A1 ES 250249 A1 ES250249 A1 ES 250249A1 ES 0250249 A ES0250249 A ES 0250249A ES 250249 A ES250249 A ES 250249A ES 250249 A1 ES250249 A1 ES 250249A1
Authority
ES
Spain
Prior art keywords
prepared
dione
methyl
hydroxy
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES0250249A
Other languages
Spanish (es)
Inventor
David H Gould
Hans Reimann
Lawrence E Finckenor
Cecil H Robinson
Eugene Oliveto
Elliot L Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherico Ltd
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US743492A external-priority patent/US2894963A/en
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of ES250249A1 publication Critical patent/ES250249A1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention comprises (1) a process for the production of 9a ,11b -dihalogeno-pregnanes and -androstanes by reacting the corresponding 9,11-dehydro compounds with a halogenating agent, or by reacting the corresponding 9a -halogeno-11a -hydroxy compound with a sulphonating agent to form the 11a -sulphonic ester and reacting this with a halide, or by reacting the corresponding 9a -halogeno-11a -amino compound with a nitrosyl halide, or by treating the corresponding 9a -halogeno-11b -amino compound first with an alkyl nitrite and then with a hydrohalic acid and (2) as new compounds, the products of (1) which contain a 3-keto group and, in the case of the pregnanes, also a 20-keto group. The process may be applied to 3-keto-9(11)- androstenes and 3,20-diketo-9(11)-pregnenes and their 19-nor-analogues which may optionally contain D 1-, D 4- or D 1,4-double bonds and/or lower alkyl, hydroxy, acyloxy, alkylenedioxy, and/or halogen substituents in the nucleus or side chains, particularly in positions 2, 6, 16, 17 and 21. The halogenating agent may be (1) molecular halogen such as chlorine or bromine (2) molecular halogen donors such as pyridinium bromide perbromide, dioxan dibromide, iodobenzene dichloride and p-iodotoluene dichloride (3) halogen halides such as iodine monochloride (4) mixtures of reagents comprising a positive halogen donor such as molecular halogen, a halogen halide or a compound such as N-chlor- or N-iodosuccinimide, N-bromoacetamide or dimethyl-N,N-dibromohydantoin together with a halogen ion of electronegativity equal to or greater than that of the positive halogen donor, which may be supplied by a salt such as a lithium or potassium halide or a hydrohalic acid or mixtures thereof and (5) fluorinating agents such as heavy metal polyfluorides or mixtures of heavy metal oxides or idosobenzene diacetate with hydrogen fluoride, antimony pentafluoride, iodine heptafluoride or bromine trifluoride. In these halogenation processes the more electronegative halogen goes to the 11-position. In a preferred process the halogenation is conducted in a halogenated hydrocarbon solvent in presence of a tertiary organic base, whereby the production of unwanted by-products is minimized. To effect halogenation wherein the more electronegative atom is attached at position 9 the processes utilising a sulphonate ester, a nitrosyl halide or an alkyl nitrite may be used. In the sulphonation process a 21-hydroxyl group must be previously protected by conversion to a 21-ester. Examples illustrate all the above processes and the D 1-dehydrogenation (using C. simplex), chemical or microbiological hydrolysis of 21-esters and esterification of 21-ols with mono- or di-carboxylic acids, sulphonic acids or inorganic acids, hydrolysis of 16-esters and preparation of 16a ,17a -alkylenedioxy derivatives from 16a ,17a -diols, degradation of the 17-side chain in 20-keto-pregnanes to give the corresponding androstan-17-ones, the reduction of these to androstan-17-ols by chemical or microbiological, e.g. using C. cerevisiae, methods and esterification of the 17-ols and esterification of 17-hydroxy groups in pregnane compounds, of the 9a ,11b -dihalogeno products. Reference is also made to oxidation, hydroxylation and alkylation of these products, and to the oxidation of 3-hydroxy- 9a ,11b - dihalogeno-17(20), 20(21)-bismethylenedioxy pregnanes to the 3-ketones and subsequent preparation of the D 4- and D 1,4-compounds by bromination and dehydrobromination or the action of C. simplex and removal of the bismethylenedioxy group. D 9(11)-Steroid starting materials are prepared by standard methods from the corresponding 11- hydroxylated compounds p sometimes with isolation of the 11a -hydroxy sulphonate esters or D 1,4,9(11)-steroid starting materials are obtained by D 1-dehydrogenation of the corresponding D 4,9(11)-steroids. 9a -Halo- 11b - hydroxysteroid starting materials are prepared from the corresponding 9b ,11b -oxido-steroids, and may subsequently be oxidized to 9a -halo-11-keto-steroids which on stereospecific reduction, if necessary with protection of a 3- and/or 20-keto group by conversion to a 3- or 3,20-bis-ethylene ketal and/or protection of a 20-keto group in a 17-hydroxy compound by conversion to a 17(20),20(21)-bis-methylenedioxy group, gives a 9a -halo-11a -hydroxy-steroid. 11a -Hydroxy steroid starting materials are prepared by hydroxylation of the 11-unsubstituted compounds using C. lunata or R. nigricans. 9a -Fluoro- 3a -hydroxy-11(a and b )amino-17a (20),20(21)- bis-methylenedioxypregnanes are prepared by reacting 9a -fluoro-cortisone with formaldehyde to give 9a -fluoro-17(20), 20(21)- bis-methylenedioxy- 4-pregnene-3,11-dione, reducing this to give 9a -fluoro-17(20), 20(21)- bismethylenedioxypregnane -3-ol-11-one, treating this with hydroxylamine to give the corresponding 11-oximino-steroid and reducing this to give a mixture of the required epimers, which are separated by chromatography. 1,4,9(11)- Pregnatriene- 17a ,21- diol- 3,20-dione is prepared by saponification of the 21-acetate. 6b -Methyl-19-nor- 4-androsten-11b -ol-3,17-dione is prepared by reacting 5a ,6a -epoxy-19-nor-androstan- 11b -ol-3,17-dione 3,17-bis-ethyleneketal with methyl magnesium bromide to give 6b -methyl-19-nor-androstane-5a ,11b -diol-3,17-dione 3,17-bismethyleneketal, hydrolysing this to 6b -methyl-19-nor-androstane-5a ,11b -diol-3,17-dione and refluxing this with sodium hydroxide. 1,4,9(11)-Androstatrien-17b -ol-3-one is prepared by reduction of the 3,17-dione and is subsequently converted to various esters. 6a -Fluoro-17a -methyl-9(11)- androsten-17b -ol-3-one is prepared by reaction of the corresponding D 4-compound with lithium in liquid ammonia. 6a -Methyl-9(11)-androsten-17b -ol-3-one is prepared similarly and is converted to the 17-propionate. 6a -Fluoro-19-nor-9(11)-androsten-3,17-dione is prepared similarly from the corresponding D 4-compound, itself prepared by dehydrogenation of of the 11b -ol. 17a -Ethyl-9(11)- androsten- 17b -ol-3-one is prepared by converting 9(11)-androstene-3,17-dione to the 3-pyrrolidylenamine and reacting this with ethyl magnesium bromide with subsequent hydrolysis. 21-Fluoro-pregnane starting materials are prepared from the 21-iodo-pregnanes, which are prepared either from the 21-ols via the 21-tosylates or from the 21-unsubstituted-pregnanes. 17a -Acetoxy-4,9(11)- pregnadiene-3,20-dione is prepared by acetylation of the 17-ol. The corresponding 1,4,9(11)-pregnatriene is prepared similarly, the 17-ol being prepared by reacting 17a ,21-dihydroxy- 1,4,9(11)- pregnatriene-3,20-dione (prepared by hydrolysis of the 21-acetate) first with tosyl chloride, then sodium iodide and then sodium bisulphite and acetic acid. 17a -Methyl-4,9(11)-pregnadiene-3,20-dione is prepared similarly from the 21-tosylate, itself prepared from the 21-ol. 17a -Chloro-progesterone is prepared by reacting 3b -acetoxy- 5-pregnene- 20-one with acetic anhydride to give 5,17(20)-pregnadiene-3b ,20-diol diacetate, reacting this with chlorine to give 3b -acetoxy-5a ,6b ,17a -trichloroallopregnan-20-one, dehalogenating this to 3b -acetoxy-17a - chloro-5-pregnen-20-one and subjecting this to a culture of F. dehydrogenans. Esters of 17a -hydroxy-21-fluoro- 4,9(11)-pregnadiene-3,20-dione are prepared from the 17-ol, itself prepared from 17a -hydroxy-21-iodo-4,9(11)-pregnadiene-3,20-dione (prepared from the 21-bromo compound), which is also converted into the 17-acetate. 6a -Methyl-17a -hydroxy- 4,9(11)-pregnadiene-3,20-dione is prepared by dehydrating 6a -methylhydrocortisone acetate to give 6a -methyl-17a ,21-dihydroxy- 4,9(11)-pregnadiene-3,20-dione 21-acetate, hydrolysing this to the 21-ol and reacting this with tosyl chloride, then sodium iodide and then sodium bisulphite, and is converted to various 17-esters. The corresponding 6a -fluoro compound is prepared by dehydration of the 11-ol and is converted to the 17-acetate. 6b ,17a -Dimethyl progesterone is prepared by converting 17a -methyl-progesterone to the 3,20-bisethyleneketal, converting this to the 5a ,6a -epoxide, reacting this with methyl magnesium iodide to give 5a -hydroxy-6b ,17a -dimethylpregnane-3,20-dione and dehydrating this. The corresponding 6b -fluoro compounds are similarly prepared via the epoxide and hydrogen fluoride. The corresponding 17a -bromo compounds are prepared similarly. 6a ,17a -Dimethyl- 4,9(11)- pregnadiene-3,20-dione is prepared by epimerization of the 6b -isomer. The corresponding 6a -fluoro compound is prepared similarly. 6a -Methyl-17a - bromoprogesterone is prepared from 5a -hydroxy-6b -methyl-17a -bromo-pregnane-3,20-dione and refluxing ethanol containing hydrochloric acid. The corresponding 6a -fluoro compound is prepared similarly. Esters of 6a -methyl-17a -hydroxy-21-fluoro-4,9(11)-pregnadiene-3,20-dione are prepared from the 17-ol. The preparation of esters of other 17-ols referred to above and below is also described. 16a -Methyl- 17a -hydroxyprogesterone is prepared by chlorinating 3b -acetoxy-16a -methyl-5-pregnen-20-one to give 3b -acetoxy-5,6-dichloro-16a -methyl-pregnan-20-one, converting this to 3b ,17a -dihydroxy-5,6-dichloro-16a -methyl-pregnan-20-one, oxidizing this to the 3,20-dione, dechlorinating this to 16a -methyl- 17a -hydroxy- 5-pregnene- 3,20-dione and isomerizing this. 16a -Ethyl-progesterone is prepared by reacting 3b -hydroxy- 5,16-pregnadien- 20-one wih ethyl magnesium iodide to give 3b -hydroxy-16a -ethyl-5-pregnen-20-one and oxidizing this by the Oppenauer method. 6a ,16a -Dimethyl- 11a ,17a -dihydroxyprogesterone is prepared by converting 11a ,17a -dihydroxy-16a -methyl-progesterone to the 3,20-bis-ethyleneketal, converting this to 5a ,6a -epoxy- 11a ,17a - dihydroxy- 16a - methylpregnane-3, 20-dione 3,20-bis-ethyleneketal, reacting this wih methyl magnesium iodide to give 5a ,11a ,17a - trihydroxy- 6b ,16a -dimeth
ES0250249A 1958-06-20 1959-06-19 9, 11-dihalogeno steroids Expired ES250249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US743492A US2894963A (en) 1958-06-20 1958-06-20 9,11-dihalogeno-4-pregnenes and 1,4-pregnadienes
CA775651 1959-05-30

Publications (1)

Publication Number Publication Date
ES250249A1 true ES250249A1 (en) 1960-01-16

Family

ID=25673299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES0250249A Expired ES250249A1 (en) 1958-06-20 1959-06-19 9, 11-dihalogeno steroids

Country Status (7)

Country Link
BE (1) BE579900A (en)
CH (1) CH386415A (en)
DK (1) DK118874B (en)
ES (1) ES250249A1 (en)
FR (1) FR564M (en)
GB (2) GB928301A (en)
NL (1) NL106036C (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3397213A (en) * 1966-01-12 1968-08-13 Squibb & Sons Inc 12 methyl-9, 11-dihaloprogesterones
FR2342738A1 (en) * 1976-03-02 1977-09-30 Roussel Uclaf NEW HALOGEN DERIVATIVES OF THE 16A-METHYL PREGNANE SERIES
DK2278978T3 (en) 2008-05-28 2015-09-21 Reveragen Biopharma Inc NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE
EP2556083A4 (en) 2010-04-05 2013-12-04 Validus Biopharma Inc Non-hormonal steroid modulators of nf- kappa b for treatment of disease
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
NL106036C (en) 1963-09-16
FR564M (en) 1961-06-05
BE579900A (en) 1959-10-16
DK118874B (en) 1970-10-19
GB928301A (en) 1963-06-12
GB928302A (en) 1963-06-12
CH386415A (en) 1965-01-15

Similar Documents

Publication Publication Date Title
US3639434A (en) 17-acyloxysteroids and their manufacture
ES250249A1 (en) 9, 11-dihalogeno steroids
US3164618A (en) Alkylated steroids
GB869511A (en) Improvements in or relating to steroids and the manufacture thereof
US3173914A (en) 5, 6-difluoro steroids and process for the preparation thereof
US3009933A (en) Process for the manufacture of 9alpha, 11beta-dihalogenated steroids
US3127425A (en) 6, 17alpha-disubstituted 9alpha, 11beta-dihalogeno derivatives of a-ring unsaturated pregnane 3, 20-diones
US3184484A (en) 5, 10-methylene-19-nor- and 5, 10-seco-5, 19-cyclo-10-fluoro-androstenes and pregnenes and processes for their preparation
US3290338A (en) 16-alkylprogesterones and their 9alpha, 11beta-dihalogeno analogs
US3131200A (en) C-ring halogenated progesterones
US3105840A (en) Alkyl ethers of 17alpha-hydroxy-19-nor progesterone
US3009938A (en) Process for the manufacture of halogenated steroids
US3637670A (en) Intermediates and process for preparing useful 17alpha-hydroxy-20-keto and 17alpha 21-dihydroxy-20-keto pregnanes and derivatives thereof
US3168537A (en) Process for the manufacture of 16-alkylidene-17alpha-alkanoyloxyprogesterones
US3793350A (en) Process for preparing 17alpha,21-dihydroxy-20-keto-pregnanes,derivatives and intermediates thereof
US3053858A (en) 10-fluoro-19-nor steroids
US3049554A (en) 9, 11-dihalogeno-3, 20-diketopregnanes and processes for their manufacture
US3009932A (en) 6-fluoro-9alpha, 11beta- 21-trihalo-progesterones
GB959377A (en) Dioxy steroids and processes for their preparation
US2888468A (en) Process for the production of delta5-3-keto and delta4-3-keto steroids
US2999103A (en) 16-nitro-alkyl steroids
US3047596A (en) 6alpha-halogen-9alpha-halogen-delta-pregnadiene-3-one compounds
US2963495A (en) 12 alpha-halo-3, 11-oxygenated-17alpha-hydroxy-20 oxo steroids of the pregnane series
GB832244A (en) Improvements in or relating to steroid compounds
GB906443A (en) Steroid compounds